Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points

Abstract

Insulin therapy was first proposed as an adjunctive therapy in patients with acute coronary syndromes (ACS) in the 1960s. Since then, numerous randomised clinical trials have been conducted to determine the efficacy and to define the role of insulin therapy in ACS. This review will discuss: 1) completed trials of insulin therapy in ACS, including both glucose-insulin-potassium (GIK) approaches and non-GIK approaches; 2) trials of insulin therapy in critically ill non-ACS patients and the lessons from these trials that can be applied to trials of insulin in ACS patients; and 3) a summary of ongoing and planned trials of insulin in ACS patients.

Keywords

acute coronary syndromes clinical trials diabetes mellitus glucose insulin review

References

1. Sodi-Pallares D , Bisteni A , Medrano GA , Testelli MR , De Micheli A. The polarizing treatment of acute myocardial infarction. Possibility of its use in other cardiovascular conditions. Dis Chest 1963;43:424–32.

2. Sodi-Pallares D , Fishleder BL , Cisneros F et al. A low sodium, high water, high potassium regimen in the successful management of some cardiovascular diseases. Preliminary clinical report. Can Med Assoc J 1960;83:243–57.

3. Sodi-Pallares D , Testelli MR , Fishleder BL et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166–81.

4. Rackley CE Russell RO Jr , Rogers WJ et al. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J 1981;102(6 Pt 1):1038–49.

5. Oliver MF Opie HL. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155–8.

6. Fath-Ordoubadi F , Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152–6.

7. Diaz R Paolasso EA , Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998;98:2227–34.

8. van der Horst IC , Zijlstra F , van't Hof AW et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003;42:784–91.

9. Rasoul S Ottervanger JP , Timmer JR et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. Int J Cardiol 2007;122(1):52–5.

10.

10. Timmer JR Svilaas T , Ottervanger JP et al. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol 2006;47:1730–1.

11.

11. van der Horst IC , Timmer JR , Ottervanger JP et al. Glucose-insulin-potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2). Am Heart J 2005;149:585–91.

12.

12. Yusuf S Mehta SR , Diaz R et al. Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J 2004;148:1068–78.

13.

13. Mehta SR Yusuf S , Diaz R et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437–46.

14.

14. Mehta SR Yusuf S , Diaz R , Paolasso E. Letters: Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial – Reply. JAMA 2005;293:2598.

15.

15. Diaz R Goyal A , Mehta SR et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298:2399–405.

16.

16. Yusuf S Mehta SR , Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519–30.

17.

17. Capes SE Hunt D , Malmberg K , Gerstein CH. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773–8.

18.

18. Deedwania P Kosiborod M , Barrett E et al. Hyperglycemia and Acute Coronary Syndrome. A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610–19.

19.

19. Goyal A Mahaffey KW , Garg J et al. Prognostic significance of the change in glucose level in the first 24 hours after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006;27:1289–97.

20.

20. Kosiborod M Inzucchi SE , Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction. Defining the optimal outcomes-based measure of risk. Circulation 2008;117:1018–27.

21.

21. Kosiborod M Rathore SS , Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalised with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005;111:3078–86.

22.

22. Lakhdar A Stromberg P , McAlpine GS. Prognostic importance of hyperglycaemia induced by stress after acute myocardial infarction. Br Med J (Clin Res Ed) 1984;288:288.

23.

23. Norhammar AM Ryden L , Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 1999;22:1827–31.

24.

24. Sewdarsen M Vythilingum S , Jialal I , Becker JP. Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. Q J Med 1989;71:461–6.

25.

25. Stranders I Diamant M , van Gelder RE et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004;164:982–8.

26.

26. Suleiman M Hammerman H , Boulos M et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 2005;111:754–60.

27.

27. Timmer JR van der Horst ICC , Ottervanger JP et al. Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. Am Heart J 2004;148:399–404.

28.

28. Wahab NN Cowden EA , Pearce NJ , Gardner MJ , Merry H , Cox LJ.

Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?

J Am Coll Cardiol 2002;40:1748–54.

29.

29. Opie LH. Glucose-insulin-potassium therapy in patients with STEMI (letter). JAMA 2008;299:2385–6.

30.

30. Arora RR Katragadda S Glucose-insulin-potassium therapy in patients with STEMI (letter). JAMA 2008;299:2386.

31.

31. Goyal A Diaz R , Mehta RS. Glucose-insulin-potassium therapy in patients with STEMI – Reply (letter). JAMA 2008;299:2387–8.

32.

32. Malmberg K Ryden L , Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57–65.

33.

33. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br Med J 1997; 314:1512–15.

34.

34. Malmberg K Ryden L , Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650–61.

35.

35. Cheung NW Wong VW , McLean M. The Hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29:765–70.

36.

36. Pittas AG Siegel RD , Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2004;164:2005–11.

37.

37. van den Berghe G , Wouters P , Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–67.

38.

38. Malhotra A. Intensive insulin in intensive care [comment]. N Engl J Med 2006;354:516–18.

39.

39. Clement S Braithwaite SS , Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553–91.

40.

40. Garber AJ Moghissi ES , Bransome ED Jr et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004;10(1):77–82.

41.

41. Van den Berghe G , Wilmer A , Hermans G et al. Intensive insulin therapy in the medical ICU. New Engl J Med 2006;354:449–61.

42.

42. Hammer L Dessertaine G , Timsit J-F Intensive insulin therapy in the medical ICU (letter). New Engl J Med 2006;354:2069–71.

43.

43. Devos P Preiser JC , Melot C. Impact of tight glycemic control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the Glucontrol study (abstract). Intensive Care Med 2007;33:S189.

44.

44. Glucontrol Trial entry on the Clinicaltrials.gov website. Available at http://clinicaltrials.gov/show/NCT00107601. Accessed on May 28, 2008.

45.

45. Brunkhorst FM Engel C , Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–39.

46.

46. Pinto DS Skolnick AH , Kirtane AJ et al. Research correspondence: U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005;46:178–80.

47.

47. Svensson AM McGuire DK , Abrahamsson P , Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005;26: 1255–61.

48.

48. Aberegg SK. Intensive insulin therapy in the medical ICU (letter). N Engl J Med 2006;354:2069–71.

49.

49. NICE-SUGAR trial website. Available at http://www.thegeorgeinstitute.org/research/critical-care-&-trauma/research/normoglycaemia-in-intensive-care-evaluation—nice.cfm. Accessed on May 30, 2008.

50.

50. NICE-SUGAR Trial entry on the Clinicaltrials.gov website. Available at http://www.clinicaltrials.gov/ct2/results?term=NCT00220987. Accessed on June 1, 2008.

51.

51. Personal email communication with Dr. Simon Finfer (principal investigator of the NICE-SUGAR trial) on June 1, 2008.

52.

52. IMMEDIATE Trial entry on the Clinicaltrials.gov website. Available at http://www.clinicaltrials.gov/ct2/results?term=NCT00091507. Accessed on May 28, 2008.

53.

53. IMMEDIATE trial website. Available at http://www.immediatetrial.com/. Accessed May 28, 2008.

54.

54. Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 2008;117:2172–7.

55.

55. SWEET-ACS trial design. Available at www.anmco.it/CentroStudi/down-load/brochure_definitiva_2007.pdf. Accessed on June 1, 2008.

56.

56. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2005;28(suppl 1):S4–S36.

57.

57. INTENSIVE Trial entry on the Clinicaltrials.gov website. Available at http://www.clinicaltrials.gov/ct2/results?term=NCT00670228. Accessed on June 1, 2008.

58.

58. RECREATE Trial entry on the Clinicaltrials.gov website. Available at http://www.clinicaltrials.gov/ct2/results?term=NCT00640991. Accessed on June 1, 2008.